A five year, the long-term assessment revealed the safety and consistency of palbociclib plus endocrine therapy for HR+/HER2- advanced breast cancer patients.
Data were collected from the three randomized studies performed on patients with HR+/HER2- advanced breast cancer that included the postmenopausal women who had not gone through any previous systemic therapy for advanced disorder and pre/postmenopausal women who had progressed on last endocrine therapy.
The total person-years of therapy exposure were 1421.6 with palbociclib plus endocrine therapy (n=872), and 528.4 with endocrine therapy (n=471). Neutropenia and infections were more familiar with palbociclib plus endocrine therapy than endocrine therapy.
Febrile neutropenia was found in 1.4% of patients administering palbociclib plus endocrine therapy. Cumulative prevalence of all-grade hematologic adverse events in both groups peaked in the first year of therapy and plateaued over the five consequent years. Thirteen patients who were administering palbociclib plus endocrine therapy and three patients who were administering endocrine therapy were found with interstitial lung disease.
Thus, the study confirmed the safety of palbociclib plus endocrine therapy for HR+/HER2- advanced breast cancer patients.
|
Source: |
Journal of the National Cancer Institute |
|
Link to the source: |
https://academic.oup.com/jnci/article/111/4/419/5055701?login=true [Last accessed on: 25 January, 2021] |
|
Original title of article: |
Long-Term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis With Up to 5 Years of Follow-Up |
|
Translated by: |